LKB1 loss cooperating with BRAF V600E promotes melanoma cell invasion and migration by up-regulation MMP-2 via PI3K/Akt/mTOR pathway.

about

LKB1 loss cooperating with BRAF V600E promotes melanoma cell invasion and migration by up-regulation MMP-2 via PI3K/Akt/mTOR pathway.

Item

http://www.wikidata.org/entity/Q48523000

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

LKB1 loss cooperating with BRA ...... P-2 via PI3K/Akt/mTOR pathway.

@en

LKB1 loss cooperating with BRA ...... P-2 via PI3K/Akt/mTOR pathway.

@nl

type

Item

label

LKB1 loss cooperating with BRA ...... P-2 via PI3K/Akt/mTOR pathway.

@en

LKB1 loss cooperating with BRA ...... P-2 via PI3K/Akt/mTOR pathway.

@nl

prefLabel

LKB1 loss cooperating with BRA ...... P-2 via PI3K/Akt/mTOR pathway.

@en

LKB1 loss cooperating with BRA ...... P-2 via PI3K/Akt/mTOR pathway.

@nl

P1476

LKB1 loss cooperating with BRA ...... P-2 via PI3K/Akt/mTOR pathway.

@en

P2093

Dan Luo

http://www.w3.org/2001/XMLSchema#string

Guoxin Song

http://www.w3.org/2001/XMLSchema#string

Li Yin

http://www.w3.org/2001/XMLSchema#string

Weiming Zhang

http://www.w3.org/2001/XMLSchema#string

Xue Han

http://www.w3.org/2001/XMLSchema#string

Zhiqiang Yin

http://www.w3.org/2001/XMLSchema#string

P2860

The LKB1 tumor suppressor kinase in human disease

LKB1 loss in melanoma disrupts directional migration toward extracellular matrix cues.

Lkb1 and Pten synergise to suppress mTOR-mediated tumorigenesis and epithelial-mesenchymal transition in the mouse bladder

Sox2 cooperates with Lkb1 loss in a mouse model of squamous cell lung cancer.

Lkb1 loss promotes tumor progression of BRAF(V600E)-induced lung adenomas

Liver kinase B1 (LKB1) in the pathogenesis of epithelial cancers

mTORC1 activation blocks BrafV600E-induced growth arrest but is insufficient for melanoma formation.

Loss of LKB1 disrupts breast epithelial cell polarity and promotes breast cancer metastasis and invasion.

Metformin accelerates the growth of BRAF V600E-driven melanoma by upregulating VEGF-A.

Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance.

P304

113847-113857

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.22943

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-12-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29371951

http://www.w3.org/2001/XMLSchema#string

P932

5768368

http://www.w3.org/2001/XMLSchema#string